Back

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course

Muri, J.; Cecchinato, V.; Cavalli, A.; Shanbhag, A. A.; Matkovic, M.; Biggiogero, M.; Maida, P. A.; Toscano, C.; Ghovehoud, E.; Danelon-Sargenti, G.; Gong, T.; Piffaretti, P.; Bianchini, F.; Crivelli, V.; Podesvova, L.; Pedotti, M.; Jarrossay, D.; Sgrignani, J.; Thelen, S.; Uhr, M.; Bernasconi, E.; Rauch, A.; Manzo, A.; Ciurea, A.; Rocchi, M. B. L.; Varani, L.; Moser, B.; Thelen, M.; Garzoni, C.; Franzetti-Pellanda, A.; Uguccioni, M.; Robbiani, D. F.

2022-05-23 immunology
10.1101/2022.05.23.493121 bioRxiv
Show abstract

Infection by SARS-CoV-2 leads to diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse COVID-19 outcomes. Instead, we discovered that antibodies against specific chemokines are omnipresent after COVID-19, associated with favorable disease, and predictive of lack of long COVID symptoms at one year post infection. Anti-chemokine antibodies are present also in HIV-1 infection and autoimmune disorders, but they target different chemokines than those in COVID-19. Monoclonal antibodies derived from COVID- 19 convalescents that bind to the chemokine N-loop impair cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising anti-chemokine antibodies associated with favorable COVID-19 may be beneficial by modulating the inflammatory response and thus bear therapeutic potential. One-Sentence SummaryNaturally arising anti-chemokine antibodies associate with favorable COVID-19 and predict lack of long COVID.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 9%
18.4%
Similar papers in this journal
2
Nature
○ 645 papers in training set
Top 0.8%
16.9%
Similar papers in this journal
3
Nature Immunology
○ 79 papers in training set
Top 0.1%
16.9%
Similar papers in this journal
50% of probability mass above
4
Nature Medicine
○ 125 papers in training set
Top 0.2%
6.7%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 30%
4.0%
Similar papers in this journal
6
Science Immunology
● 88 papers in training set
Top 0.7%
4.0%
7
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 19%
2.8%
8
Cell
○ 431 papers in training set
Top 4%
2.6%
9
Journal of Experimental Medicine
● 119 papers in training set
Top 1%
2.4%
10
Nature Microbiology
○ 155 papers in training set
Top 2%
1.7%
11
Science Advances
● 1243 papers in training set
Top 20%
1.7%
12
Immunity
○ 67 papers in training set
Top 1.0%
1.7%
13
Cell Research
○ 51 papers in training set
Top 0.8%
1.1%
14
Journal of Clinical Investigation
● 179 papers in training set
Top 4%
1.1%
15
Cell Reports
○ 1498 papers in training set
Top 23%
1.1%
16
Science
● 477 papers in training set
Top 7%
1.1%
17
Cell Reports Medicine
○ 153 papers in training set
Top 5%
0.8%
18
Nature Aging
○ 60 papers in training set
Top 2%
0.8%
19
Communications Biology
○ 993 papers in training set
Top 30%
0.8%
20
Nature Biotechnology
○ 172 papers in training set
Top 5%
0.6%
21
Nature Biomedical Engineering
○ 47 papers in training set
Top 2%
0.6%
22
Nature Structural & Molecular Biology
236 papers in training set
Top 4%
0.6%
23
Nature Cardiovascular Research
○ 33 papers in training set
Top 1.0%
0.6%
24
Nature Chemical Biology
○ 119 papers in training set
Top 3%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.